USPTO rules for ABBV—against CHRS—in Humira IPR re ‘166 patent: https://twitter.com/AndyBiotech/status/795677566719946758 This is the opposite result that the USPTO reached on the Humira IPR for the ‘135 patent (#msg-122698047).